LA JOLLA, CA, April 30, 2024 – Enlaza Therapeutics, the first covalent biologic platform company, today announced a $100 million Series A financing. The financing will be used to further...
BioSyntech specialized in the development, manufacturing and commercialization of biotherapeutic thermogels for regenerative medicine (tissue repair) and therapeutic delivery. The company’s assets were acquired in 2010 by Piramal Healthcare Ltd.
BioSyntech
Laval, Quebec
© 2024 Pappas Capital, LLC. ALL RIGHTS RESERVED.